Literature DB >> 34849639

Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration.

Chloé Dimeglio1,2, Fabrice Herin3,4, Isabelle Da-Silva1, Marion Porcheron1, Guillaume Martin-Blondel2,5, Sabine Chapuy-Regaud1, Jacques Izopet1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34849639      PMCID： PMC8690160          DOI： 10.1093/cid/ciab984

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


× No keyword cloud information.
  3 in total

1.  Never say "never the twain shall meet": Combining antiretroviral therapy and RNA vaccine to obtain an adequate humoral immune response in people living with HIV.

Authors:  Jean-Pierre Routy; Stéphane Isnard
Journal:  Lancet Reg Health Eur       Date:  2022-01-25

2.  Antibody titers and breakthrough infections with Omicron SARS-CoV-2.

Authors:  Chloé Dimeglio; Marion Migueres; Jean-Michel Mansuy; Sylvie Saivin; Marcel Miedougé; Sabine Chapuy-Regaud; Jacques Izopet
Journal:  J Infect       Date:  2022-02-03       Impact factor: 38.637

3.  SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.

Authors:  Ignacio Torres; Estela Giménez; Eliseo Albert; Joao Zulaica; Beatriz Álvarez-Rodríguez; Javier S Burgos; Salvador Peiró; Ramón Limón; Hermelinda Vanaclocha; Celia Rodado; Pilar Botija; Amelia Sifre; Borja Tur; Rosa Andrés Lozano; Iria Orosa; MªÁngeles Vicente-Ruiz; Ramón J Carrión; Maria Á Clari; José Sánchez-Payá; Javier Díez-Domingo; Iñaki Comas; Fernando González-Candelas; Ron Geller; David Navarro
Journal:  J Med Virol       Date:  2022-05-25       Impact factor: 20.693
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.